CCCardiol CroatCardiologia CroaticaCardiol. Croat.1848-543X1848-5448Croatian Cardiac SocietyCC 2022 17_9-10_16710.15836/ccar2022.167Chronic coronary artery diseaseAssociation of galectin-3 and significant atherosclerotic epicardial artery disease in patients with chronic coronary syndromehttps://orcid.org/0000-0002-0223-4287BošnjakIvica1*https://orcid.org/0000-0002-8076-4398BedekovićDražen1https://orcid.org/0000-0002-9890-6489Selthofer-RelatićKristina12https://orcid.org/0000-0002-3747-9305RoguljićHrvoje123https://orcid.org/0000-0002-8861-5987Bilić-ĆurčićInes12University Hospital Centre Osijek, Osijek, CroatiaFaculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, CroatiaFaculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Osijek, CroatiaADDRESS FOR CORRESPONDENCE: Ivica Bošnjak, Klinički bolnički centar Osijek, J. Huttlera 4, HR-31000 Osijek, Croatia. / Phone: +385-91-922-7756 / E-mail: dribosnjak79@gmail.com112022179-1016716725102022101120222022Croatian Cardiac SocietyKEYWORDS: galectin-3coronary artery diseasebiomarkerchronic coronary syndrome
Background: The aim of this study is to examine possible association between serum galectin-3 values and the presence of significant atherosclerotic epicardial artery disease in patients with chronic coronary syndrome.
Patients and Methods: Subjects with suspected coronary artery disease and indication for coronary angiography were included in study. Subject were divided in three groups: a) subject with indication for PCI, b) subject with indication for CABG and control group (without coronary artery disease). Galectin-3 value was measured by enzyme immunoassay (EIA) test.
Results: T-test and ANOVA variance analysis was performed for statistically analysis (SPSS program, version 17.0). The mean value of galectin-3 in the study group was statistically higher than in control group (19.98 ng/ml vs. 9.51 ng/ml, p<0.001). In subgroup analysis there was no statistically significant difference in the values of galectin-3 between the PCI and CABG groups (18.84 ng/ml vs. 21.27 ng/ml (t=7.417, p<0.001).
Conclusion: Galectin-3 has shown potential to be reliable marker for assessment of significant coronary disease existence as well as a predictor of adverse cardiovascular events (1-3).
LITERATURELiMGuoKHuangXFengLYuanYLiJAssociation Between Serum Galectin-3 Levels and Coronary Stenosis Severity in Patients With Coronary Artery Disease.Front Cardiovasc Med. 2022 February 7;9:818162. 10.3389/fcvm.2022.81816235198615BlandaVBracaleUMDi TarantoMDFortunatoG. Galectin-3 in Cardiovascular Diseases.Int J Mol Sci. 2020 December 3;21(23):9232. 10.3390/ijms2123923233287402BosnjakIBedekovicDSelthofer-RelaticKBillic-CurcicI. Galectin-3: A Heart Failure Biomarker as Sign of Active Coronary Heart Disease.World J Cardiovasc Dis. 2017;7(11):373–9. 10.4236/wjcd.2017.711035